Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy hopes to shrink spleens and ease symptoms in Tough-to-Treat myelofibrosis

NCT ID NCT06414681

Recruiting now Disease control Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a combination of two drugs, tagraxofusp and pacritinib, in about 20 adults with myelofibrosis (a bone marrow disorder) who have already tried standard JAK inhibitors or cannot use them. The main goals are to see if the combo can shrink an enlarged spleen and improve symptoms like fatigue and pain. Researchers will also monitor side effects and overall feasibility.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELOFIBROSIS (MF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELOFIBROSIS (MF)

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Kansas Cancer Center

    RECRUITING

    Fairway, Kansas, 66204, United States

    Contact Email: •••••@•••••